ACIU logo

AC Immune SA (ACIU)

$2.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ACIU

Market cap

$214742239

EPS

-0.88

P/E ratio

--

Price to sales

58.13

Dividend yield

--

Beta

1.641019

Price on ACIU

Previous close

$2.09

Today's open

$2.06

Day's range

$2.03 - $2.13

52 week range

$2.02 - $3.90

Profile about ACIU

CEO

Andrea Pfeifer

Employees

122

Headquarters

Lausanne,

Exchange

NASDAQ Global Market

Shares outstanding

101773573

Issue type

Common Stock

ACIU industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ACIU

AC Immune to Present at Jefferies Global Healthcare Conference 2026

AC Immune to Present at Jefferies Global Healthcare Conference 2026  Lausanne, Switzerland, November 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today announced that Martin Zügel, Interim CEO, will present and participate in a fireside chat at the annual Jefferies Global Healthcare Conference 2026, taking place November 16-19 in London, UK. The session will begin with a brief company presentation by Martin, followed by a fireside chat hosted by Alyna Shamsi, Equity Research Analyst at Jefferies.

news source

GlobeNewsWire • Nov 11, 2026

news preview

AC Immune Third Quarter 2026 Financial and Corporate Update

AC Immune announces financial and corporate updates for the quarter ended September 30, 2026, with positive progress across its wholly-owned pipeline.

news source

GlobeNewsWire • Nov 4, 2026

news preview

AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Best Momentum Stock to Buy for September 30th

SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.

news source

Zacks Investment Research • Sep 30, 2026

news preview

AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals

AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.

news source

MarketBeat • Sep 26, 2026

news preview

AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions

AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease. Progress in the pipeline includes Takeda-partnered ACI-24 for prodromal Alzheimer's, triggering a $12M milestone and showing antibody responses at all dose levels. Brain-penetrant NLRP3 inhibitor ACI-19764 advances, with phase 1/1b initial data at the end of 2026 and final data in the 1st half of 2027, targeting neuroinflammatory and metabolic disorders.

news source

Seeking Alpha • Sep 24, 2026

news preview

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson's disease (PD). The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity as the basis for a Phase 3 decision.

news source

GlobeNewsWire • Sep 23, 2026

news preview

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.

news source

GlobeNewsWire • Aug 20, 2026

news preview

AC Immune First Half 2026 Financial and Corporate Update

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer's disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda Cash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027 Lausanne, Switzerland, August 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today provided a corporate and financial update for the half-year ended June 30, 2026. Martin Zügel, MD, interim CEO of AC Immune and Chair of the Board of Directors, commented: “AC Immune is moving towards key clinical milestones in two of our wholly-owned programs, a growing focus for AC Immune.

news source

GlobeNewsWire • Aug 5, 2026

news preview

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.

news source

Zacks Investment Research • Aug 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in AC Immune SA

Open an M1 investment account to buy and sell AC Immune SA commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ACIU on M1